R&D Program
Our Pipeline
China Progress
US Progress
| TA | Product | Indication | Research | IND Enabling | Clinical Stage | Regulatory Designation |
||
| Phase 1 | Phase 2 | Phase 3 | ||||||
| OPHTHALMOLOGY | FT-001 | RPE65 mutation IRDs |
|
CDE Breakthrough | ||||
| FT-002 | XLRP |
|
FDA ODD FDA Fast Track |
|||||
| FT-003 | nAMD |
|
||||||
| DME |
|
|||||||
| DR |
|
|||||||
| FT-019 | Degenerative disorder |
|
||||||
| FT-023 | nAMD |
|
||||||
| DME |
|
|||||||
| DR |
|
|||||||
| CARDIOLOGY | FT-017 | HCM |
|
|||||
| FT-018 | ARVC |
|
||||||
| NEUROLOGY | FT-022 | PD |
|
|||||
沪公网安备31011502401398号